Related Experiment Video
Updated: Feb 9, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Therapeutic strategies for idiopathic chylothorax
Ralph Epaud1, Beatrice Dubern, Michele Larroquet
1Hôpital Armand Trousseau, Université Pierre et Marie Curie-Paris 6, Paris, France. ralph.epaud@trs.aphp.fr
Insights
Idiopathic chylothorax in children can be managed with a medium-chain triglyceride diet, sometimes supplemented with total parenteral nutrition. Pleuroperitoneal shunting is an option for refractory cases.
Area of Science:
- Pediatric Pulmonology
- Thoracic Surgery
- Pediatric Gastroenterology
Background:
- Idiopathic chylothorax is a rare but serious condition in children.
- Diagnosis relies on identifying chylous pleural effusion with specific triglyceride and cellularity levels.
Purpose of the Study:
- To present institutional experience with pediatric idiopathic chylothorax.
- To propose effective therapeutic strategies for this condition.
Main Methods:
- Retrospective, single-center study of 6 children diagnosed with idiopathic chylothorax.
- Evaluation of symptoms, diagnostic findings, and treatment outcomes.
Main Results:
- Median age of onset was 7 years; common symptoms included cough and asthenia.
- All patients initially received a medium-chain triglyceride diet; 4 required total parenteral nutrition.
- Pleuroperitoneal shunting was necessary in 2 children. Chylothorax stabilized in all patients during follow-up.
Conclusions:
- A medium-chain triglyceride diet, potentially with total parenteral nutrition, can stabilize pediatric idiopathic chylothorax.
- Pleuroperitoneal shunting is a viable option for cases unresponsive to conservative management.
Study Objectives:
The objectives of the study were to present our institutional experience of idiopathic chylothorax in children and to propose therapeutic strategies.
Design:
This was a retrospective, single-center study.
Patients:
Patients were 6 children (4 boys, 2 girls) presenting with an idiopathic chylothorax diagnosed from the presence of a chylous pleural effusion with triglycerides greater than 1.2 mmol/L and a cellularity greater than 1000 cells/mL with a predominance of lymphocytes.
Results:
Median age of onset was 7 years (range, 2-14 years). Initial symptoms included cough (n = 4), tachypnea (n = 4), asthenia (n = 5), abdominal pain (n = 2), and bronchitis (n = 1). Chest radiography showed 2 left, 2 right, and 2 bilateral pleural effusions. Serum biology assessment was normal in all children. Respiratory function assessment at diagnosis revealed a decrease in functional residual capacity in 3 children and a decrease in lung diffusing capacity in 2 children. Initially, all patients received a medium-chain triglyceride diet for 29 months (range, 10-50 months). Total parenteral nutrition was required for 4 patients (for 1-4 months), and somatostatin was tried in one child. Two children required pleuroperitoneal shunting, bilateral in one case. During the follow-up (median duration, 6 years; range, 2-16 years), chylothorax stabilized in all patients and 5 patients were able to return to a normal diet.
Conclusion:
A medium-chain triglyceride diet associated in some cases with total parenteral nutrition may stabilize idiopathic chylothorax in children. In cases where conservative treatment has failed, pleuroperitoneal shunting may be useful.
More Related Videos
09:19High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
08:08Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
Published on: October 16, 2013
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Persuasion Strategies
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...